StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Level 3 Rollforward by Year

Level 3 Rollforward — Change in Fair Value Recognized in Earnings ($M) ($M)

AbbVie Level 3 Rollforward: $6,495M in FY2025, up 72.2% from a year earlier. That is the highest of the 11 years on record here.

Latest, FY2025
6,495
Period ended Dec 31, 2025
Change on a year earlier
+72.2%
3,771 in FY2024
History
11 years
Since FY2015
Sources
9
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-20) ↗

Reported in Form 10-Q / 10-K Fair Value Measurements Note.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedLevel 3 Rollforward — Change in Fair Value Recognized in Earnings ($M) ($M)Year on yearSource
FY2025Dec 31, 20256,495+72.2%Form 10-K (filed 2026-02-20) ↗
FY2024Dec 31, 20243,771-26.5%Form 10-K (filed 2026-02-20) ↗
FY2023Dec 31, 20235,128+85.7%Form 10-K (filed 2026-02-20) ↗
FY2022Dec 31, 20222,761+3.1%Form 10-K (filed 2025-02-14) ↗
FY2021Dec 31, 20212,679-53.4%Form 10-K (filed 2024-02-20) ↗
FY2020Dec 31, 20205,753+86.1%Form 10-K (filed 2023-02-17) ↗
FY2019Dec 31, 20193,091+6,208.2%Form 10-K (filed 2022-02-18) ↗
FY2018Dec 31, 201849-92.2%Form 10-K (filed 2021-02-19) ↗
FY2017Dec 31, 2017626+174.6%Form 10-K (filed 2020-02-21) ↗
FY2016Dec 31, 2016228–Form 10-K (filed 2019-02-27) ↗
FY2015Dec 31, 20150–Form 10-K (filed 2018-02-16) ↗

Cite this data

StockData. (2026). AbbVie Level 3 Rollforward ($M), annual FY2015–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/cc-fv-change

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.